Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Novel Mechanisms of Venetoclax Resistance in Acute Myeloid Leukemia Based on Genomic Rearrangements

Irene Zacheo, Anna Ferrari, Eugenio Fonzi, Maria Teresa Bochicchio, Giorgia Capirossi, Jacopo Nanni, Matteo Paganelli, Chiara Servilli, Lorenzo Ledda, Martina Ghetti, Mouna Jandoubi, Matteo Marchesini, Agnese Mattei, Giovanni Martinelli, Giovanni Marconi, Giorgia Simonetti

Blood (2023) 142 (Supplement 1): 4165.

https://doi.org/10.1182/blood-2023-189435

Published: 2023

Journal Articles

Centralized MRD Assessment at Early Timepoints in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk AML

Blood (2023) 142 (Supplement 1): 1567.

https://doi.org/10.1182/blood-2023-189777

Published: 2023

Journal Articles

Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1536.

https://doi.org/10.1182/blood-2023-184678

Published: 2023

Journal Articles

Pre-Existing Myeloid Subclones May Account for a Subset of Acute Myeloid Leukemias and Myelodysplastic Neoplasms in Patients with Pre-Existing or Contemporary Lymphoid Disorders

Agnese Mattei, Giovanni Marconi, Sonia Ronconi, Delia Cangini, Michela Ceccolini, Claudio Cerchione, Irene Zacheo, Maria Benedetta Giannini, Marianna Norata, Giovanni Martinelli, Anna Ferrari, Maria Teresa Bochicchio, Martina Ghetti, Matteo Marchesini, Giorgia Simonetti, Gerardo Musuraca, Davide Nappi

Blood (2023) 142 (Supplement 1): 1475.

https://doi.org/10.1182/blood-2023-186760

Published: 2023

Journal Articles

Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 1705–1707.

https://doi.org/10.1182/blood-2022-157393

Published: 2022

Journal Articles

Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 6119–6121.

https://doi.org/10.1182/blood-2022-157937

Published: 2022

Journal Articles

Preferential Use of Coagulation Pathways Differs between Classical Myeloproliferative Neoplasms: Results of Global Coagulation Assays with Respect to Clinical and Genetic Features

Alessandro Lucchesi, Roberta Napolitano, Maria Teresa Bochicchio, Giorgia Simonetti, Giorgia Micucci, Monica Poggiaspalla, Valeria Di Battista, Gerardo Musuraca, Giovanni Martinelli, Giulio Giordano, Flavia Foca, Lucia Catani, Mariasanta Napolitano

Blood (2022) 140 (Supplement 1): 12160–12161.

https://doi.org/10.1182/blood-2022-171095

Published: 2022

Journal Articles

IDH1/2 Mutations Are Maintained in a Subset of Patients with Acute Myeloid Leukemia in Complete Remission and Do Not Correlate with Residual Disease

Giovanni Marconi, Lorenza Bandini, Agnese Patuelli, Chiara Sartor, Sarah Parisi, Jacopo Nanni, Gianluca Cristiano, Letizia Zannoni, Giorgia Simonetti, Maria Teresa Bochicchio, Emanuela Ottaviani, Giovanni Martinelli, Stefania Paolini, Cristina Papayannidis, Michele Cavo, Antonio Curti

Blood (2021) 138 (Supplement 1): 4446.

https://doi.org/10.1182/blood-2021-149450

Published: 2021

Journal Articles

A Comparison of Droplet Digital PCR and RT-qPCR for BCR-ABL1 Monitoring in Chronic Myeloid Leukemia

Carmen Fava, Paola Berchialla, PhD, Jessica Petiti, PhD, Maria Teresa Bochicchio, Barbara Izzo, PhD, Emilia Giugliano, Emanuela Ottaviani, Santa Errichiello, PhD, Giovanna Rege Cambrin, MD PhD, Claudia Venturi, Luigiana Luciano, Filomena Daraio, Daniele Calistri, Alessandro Martino, Giuseppe Saglio, MD, Giovanni Martinelli, MD, Fabrizio Pane, MD, Daniela Cilloni, MD PhD, Enrico Marco Gottardi

Blood (2019) 134 (Supplement_1): 2092.

https://doi.org/10.1182/blood-2019-125614

Published: 2019

Journal Articles

The Prolonged Inhibition of Chk1/Chk2 Kinases Enhances Genetic Instability and Compromises the Efficacy of Chemotherapy Against Acute Lymphoblastic Leukemia Cells

Andrea Ghelli Luserna Di Rorà, PhD, Antonella Padella, PhD, Maria Chiara Fontana, PhD, Eugenio Fonzi, PhD, Anna Ferrari, PhD, Enrica Imbrogno, PhD, Martina Ghetti, PhD, Roberta Napolitano, PhD, Maria Teresa Bochicchio, Giovanni Martinelli, MD, Giorgia Simonetti, PhD

Blood (2019) 134 (Supplement_1): 5047.

https://doi.org/10.1182/blood-2019-129964

Published: 2019

Journal Articles

Biology of Acute Myeloid Leukemia (AML) with Monosomy of Chromosome 7 or Loss of 7q. a Study on 487 Patients Analyzed By Gene Expression Profile (GEP), Single Nucleotide Polymorphism (SNP) Arrays and Metabolomics

Blood (2018) 132 (Supplement 1): 2748.

https://doi.org/10.1182/blood-2018-99-118183

Published: 2018

Journal Articles

Mitoxantrone, Etoposide and Cytarabine (MEC) Can Induce Deep Complete Remission and Is an Effective Bridge Therapy to Allotransplantation (SCT) in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients

Blood (2018) 132 (Supplement 1): 4036.

https://doi.org/10.1182/blood-2018-99-113036

Published: 2018

Journal Articles

Negative Prognostic Relevance of a Specific 3-Gene Cluster in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Blood (2018) 132 (Supplement 1): 4347.

https://doi.org/10.1182/blood-2018-99-112062

Published: 2018

Journal Articles

An Italian Multicentre Study Using Different Digital PCR Instruments on BCR-ABL1 Positive Patients at Different Levels of CML Disease

Filomena Daraio, PhD, Emilia Giugliano, Carmen Fava, MD PhD, Roberta Lorenzatti, Dr., Marta Varotto, Dr., Davide Barberio, Dr., Simona Bernardi, PhD, Barbara Izzo, PhD, Santa Errichiello, PhD, Maria Teresa Bochicchio, Claudia Venturi, Dr., Francesco Albano, MD, Giuseppe Saglio, MD PhD, Fabrizio Pane, MD, Giovanni Martinelli, MD, Giorgina Specchia, MD, Domenico Russo, MD, Enrico Marco Gottardi, Dr.

Blood (2017) 130 (Supplement 1): 4176.

https://doi.org/10.1182/blood.V130.Suppl_1.4176.4176

Published: 2017

Journal Articles

First-Line Dasatinib in BCR-ABL1+ Chronic Myeloid Leukemia in Early Chronic Phase: A Gimema Prospective Multicentric Observational Study

Blood (2017) 130 (Supplement 1): 1604.

https://doi.org/10.1182/blood.V130.Suppl_1.1604.1604

Published: 2017

Journal Articles

Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML)

Blood (2016) 128 (22): 1679.

https://doi.org/10.1182/blood.V128.22.1679.1679

Published: 2016

Journal Articles

One-Step Quantitative Molecular Approach for Detection of BCR/ABL1 Rearrangement and for Monitoring of Minimal Residual Disease in CML Patients: An Inter Laboratory Study

Filomena Daraio, PhD, Maria Teresa Bochicchio, Dr., Barbara Izzo, PhD Prof., Claudia Venturi, Dr., Santa Errichiello, PhD, Francesca Crasto, Dr., Giovanna Rege-Cambrin, MD, Roberta Lorenzatti, Dr., Carmen Fava, MD, Fausto Castagnetti, MD, Fabrizio Pane, MD Prof., Giovanni Martinelli, MD Prof., Giuseppe Saglio, MD Prof., Enrico Marco Gottardi, Dr.

Blood (2016) 128 (22): 5423.

https://doi.org/10.1182/blood.V128.22.5423.5423

Published: 2016

Journal Articles

Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR 4.0 , MR 4.5 And MR 5.0 ) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR)

Blood (2016) 128 (22): 3096.

https://doi.org/10.1182/blood.V128.22.3096.3096

Published: 2016

Journal Articles

Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia

Blood (2015) 126 (23): 2513.

https://doi.org/10.1182/blood.V126.23.2513.2513

Published: 2015

Journal Articles

Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients

Blood (2015) 126 (23): 3198.

https://doi.org/10.1182/blood.V126.23.3198.3198

Published: 2015

NARROW

Novel Mechanisms of Venetoclax Resistance in Acute Myeloid Leukemia Based on Genomic Rearrangements

Centralized MRD Assessment at Early Timepoints in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk AML

Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Pre-Existing Myeloid Subclones May Account for a Subset of Acute Myeloid Leukemias and Myelodysplastic Neoplasms in Patients with Pre-Existing or Contemporary Lymphoid Disorders

Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation

Preferential Use of Coagulation Pathways Differs between Classical Myeloproliferative Neoplasms: Results of Global Coagulation Assays with Respect to Clinical and Genetic Features

IDH1/2 Mutations Are Maintained in a Subset of Patients with Acute Myeloid Leukemia in Complete Remission and Do Not Correlate with Residual Disease

A Comparison of Droplet Digital PCR and RT-qPCR for BCR-ABL1 Monitoring in Chronic Myeloid Leukemia

The Prolonged Inhibition of Chk1/Chk2 Kinases Enhances Genetic Instability and Compromises the Efficacy of Chemotherapy Against Acute Lymphoblastic Leukemia Cells

Biology of Acute Myeloid Leukemia (AML) with Monosomy of Chromosome 7 or Loss of 7q. a Study on 487 Patients Analyzed By Gene Expression Profile (GEP), Single Nucleotide Polymorphism (SNP) Arrays and Metabolomics

Mitoxantrone, Etoposide and Cytarabine (MEC) Can Induce Deep Complete Remission and Is an Effective Bridge Therapy to Allotransplantation (SCT) in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients

Negative Prognostic Relevance of a Specific 3-Gene Cluster in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

An Italian Multicentre Study Using Different Digital PCR Instruments on BCR-ABL1 Positive Patients at Different Levels of CML Disease

First-Line Dasatinib in BCR-ABL1+ Chronic Myeloid Leukemia in Early Chronic Phase: A Gimema Prospective Multicentric Observational Study

Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML)

One-Step Quantitative Molecular Approach for Detection of BCR/ABL1 Rearrangement and for Monitoring of Minimal Residual Disease in CML Patients: An Inter Laboratory Study

Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR 4.0 , MR 4.5 And MR 5.0 ) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR)

Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia

Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only